Phathom Pharmaceuticals, Inc.
6.22USD
-0.0600 (-0.96%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PHAT.
| In $M except per-share | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85 | 74 | 58 | 58 | 50 | 40 | 29 | 30 |
| Cost of Revenue | 18 | 15 | 12 | 8 | 6 | 5 | 4 | 4 |
| Gross Profit | 66 | 59 | 46 | 50 | 43 | 34 | 25 | 26 |
| Operating Income | -0 | -4 | -15 | -6 | -15 | -60 | -79 | -59 |
| Net Income | -14 | -18 | -30 | -21 | -30 | -76 | -94 | -74 |
| EPS (Diluted) | -$0.16 | -$0.21 | -$0.37 | -$0.27 | -$0.41 | -$1.05 | -$1.31 | -$1.00 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)